Drug trial aims to make risky thyroid cancer surgery safer
NCT ID NCT04321954
Summary
This study is testing whether giving a drug called lenvatinib before surgery can improve outcomes for people with advanced thyroid cancer that has grown beyond the thyroid gland. The goal is to see if the drug shrinks tumors enough to allow surgeons to remove more cancer completely and reduce the complexity and risks of the operation. About 30 adults with specific types of invasive thyroid cancer will receive the drug for a period before their planned surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.